Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907693 · ClinicalTrials.gov registry record
The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI
A clinical trial of Pulmonary Arterial Hypertension, sponsored by Prisma Health-Upstate.
- Active
- Registry status
- 7
- Enrollment target
- 1
- Study location
NCT06907693 is a study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by Prisma Health-Upstate. The registered enrollment target is 7 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06907693, a study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by Prisma Health-Upstate.
- ACTIVE NOT RECRUITING
- Registry status
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH). This sub-study for CS1-004 aims to utilize FRI, an innovative, non-invasive imaging technology to visualize how long-term use of CS1 influences structural changes in pulmonary arteries. This sub-study seeks to provide valuable insights into the potential of CS1 to transform PAH treatment in some patients enrolled in the Expanded Access Program (CS1-004).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST CT Pulmonary Angiography Scan
Study Locations (1)
South Carolina
- Prisma Health - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2025-03-14 |
| Est. Completion | 2026-03-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06907693
The ClinicalTrials.gov registry entry for NCT06907693 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (98% lower). The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which CT Pulmonary Angiography Scan is the first listed.
NCT06907693 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT06907693 about?
NCT06907693 is a clinical study titled "The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI". Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH). This sub-study for CS1-004 aims to utilize FRI, an innovative, non-invasive imaging technology to visualize how long-term use of CS1 influenc...
What is the current status of trial NCT06907693?
This trial is currently active not recruiting. The enrollment target is 7 participants. The study started on 2025-03-14. Estimated completion is 2026-03-15.
What conditions does trial NCT06907693 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT06907693?
The interventions under investigation include: CT Pulmonary Angiography Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06907693?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06907693 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.